Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7002732 | 0.84 | — | — | |
| SCHEMBL3544761 | 0.80 | KDM4E (0.36) | KDM4EKMT2ASMYD3OPRM1 | |
| SCHEMBL3654075 | 0.79 | ALDH1A1 (0.35) | PKM | |
| SCHEMBL8787565 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL22323181 | 0.78 | KDM4E (0.35) | KDM4EKMT2ASMYD3OPRM1 | |
| SCHEMBL5474500 | 0.77 | ALDH1A1 (0.39) | PKM | |
| SCHEMBL20742723 | 0.76 | KDM4E (0.39) | KDM4E | |
| Hydrochloric Acid SCHEMBL20502496 | 0.76 | ALDH1A1 (0.38) | — | |
| SCHEMBL15774458 | 0.76 | KDM4E (0.41) | KDM4EKMT2A | |
| SCHEMBL14173382 | 0.75 | TP53 (0.40) | KDM4EKMT2ASMYD3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145628-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NOVO NORDISK A/S (DK) | 2025-05-08 | — | — | US | disclosed |
| CN-119301126-A | Pyrazolopyrimidine compound, composition containing pyrazolopyrimidine compound and application of pyrazolopyrimidine compound | 诺和诺德股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-4479402-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Novo Nordisk A/S (DK) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023155004-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | INVERSAGO PHARMA INC. (CA) | 2023-08-24 | — | — | WO | disclosed |
| EP-3233077-A1 | DOPAMINE D2 RECEPTOR LIGANDS | The Broad Institute Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100940-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145628-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | CNR1, CNR2, TRPV1 | KDM4E 2777/4885KMT2A 3336/4885PKM 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.